Donafenib Plus Sintilimab for Advanced HCC
NCT05162352
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Donafenib+sintilimab
Sponsor
Second Affiliated Hospital of Guangzhou Medical University